Global X Genomics & Biotechnology ETF (GNOM) Price, Holdings, & News

ETF Overview

Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center. Its customers include some of the global academic and government research centers and biopharmaceutical companies. Effective March 18, 2013, BGI-Shenzhen announced that through its wholly-owned subsidiary, Beta Acquisition Corporation, it has completed the acquisition of the Company.

Key Stats

• Today's Range: $36.72 to $37.44
• 50-Day Range: $8.36 to $37.03
• 52-Week Range: $27.20 to $46.72
• Volume: 9,565 shs
• Average Volume: 15,537 shs
• Market Capitalization: $185.84 million
• Assets Under Management: $46.38 million
• Dividend Yield: N/A
• Net Expense Ratio: 0.50%
• Aggregate Rating: Moderate Buy

GNOM ETF - Frequently Asked Questions

How have GNOM shares performed this year?

Global X Genomics & Biotechnology ETF's stock was trading at $38.84 at the beginning of the year. Since then, GNOM stock has decreased by 4.8% and is now trading at $36.9740.

When did Global X Genomics & Biotechnology ETF's stock split?

Shares of Global X Genomics & Biotechnology ETF reverse split on Tuesday, September 2nd 2025.A 1-4 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 1st 2025. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

Who are Global X Genomics & Biotechnology ETF's major shareholders?

Top institutional investors of Global X Genomics & Biotechnology ETF include Flow Traders U.S. LLC (4.76%), Bank of America Corp DE (2.52%), Oppenheimer Asset Management Inc. (1.79%) and Insight Advisors LLC PA (1.19%).

How do I buy shares of Global X Genomics & Biotechnology ETF?

Shares of GNOM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Global X Genomics & Biotechnology ETF own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Global X Genomics & Biotechnology ETF investors own include Meta Platforms (META), NVIDIA (NVDA), Teladoc Health (TDOC), Intel (INTC), Alibaba Group (BABA) and PayPal (PYPL).

Fund Details

• Issuer: Global X
• Fund Name: Global X Genomics & Biotechnology ETF
• Tax Classification: Regulated Investment Company
• Stock Exchange: NASDAQ
• Current Symbol: NASDAQ:GNOM
• Inception Date: 4/5/2019
• Fund Manager: Chang Kim, James Ong, Nam To, Wayne Xie
• Web: www.completegenomics.com
• Phone: +1-650-9432800

Fund Focus

• Asset Class: Equity
• Benchmark: Solactive Genomics Index
• Category: Strategy
• Focus: Theme
• Development Level: Blended Development
• Region: Global
• Number of Holdings: 49

Fund Statistics

• Assets Under Management: $46.07 million
• Average Daily Volume: $0.00
• Discount/Premium: 0.00%

Administrator, Advisor and Custodian

• Administrator: Global X Management Company LLC
• Advisor: Global X Management Company LLC
• Custodian: Brown Brothers Harriman & Co.
• Distributor: SEI Investments Distribution Co.
• Transfer Agent: Brown Brothers Harriman & Co.
• Trustee: N/A
• Lead Market Maker: Susquehanna

Options

• Optionable: Optionable
• Options Volume: 2
• Put Options: 2
• Call Options: 1
• Short Interest: 27,300 shs

Miscellaneous

• Outstanding Shares: 5,020,000
• Beta: 1.03
• Creation Unit: 50,000
• Creation Fee: $500.00